Table 3. Factors associated with completing ⩾4 cycles in patients who started chemotherapy.

	Total N=8768a	%	Received ⩾4 cycles N=5540 (63%)	%	OR for completing ⩾4 cycles	95% CI	Adjusted ORb	95% CI
Sex
Female	4166	47.5	2641	63.4	1.00		1.00
Male	4602	52.5	2899	63.0	0.98	0.90–1.07	0.99	0.91–1.09
Age group
<55	895	10.2	618	69.1	1.41	1.19–1.68	1.29	1.07–1.54
55–59	1106	12.6	755	68.3	1.36	1.16–1.60	1.26	1.07–1.49
60–64	1620	18.5	1058	65.3	1.19	1.03–1.38	1.15	0.99–1.34
65–69	1777	20.3	1169	65.8	1.22	1.06–1.40	1.21	1.05–1.40
70–74	1625	18.5	995	61.2	1.00		1.00
75–79	1147	13.1	645	56.2	0.81	0.70–0.95	0.83	0.71–0.98
80–84	496	5.7	244	49.2	0.61	0.50–0.75	0.63	0.52–0.78
⩾85	102	1.2	56	54.9	0.77	0.52–1.15	0.80	0.53–1.21
Townsend quintile (socio-economic status)
1 (Least deprived)	1241	14.2	801	64.5	1.00		1.00
2	1590	18.1	1032	64.9	1.02	0.87–1.19	0.99	0.84–1.16
3	1743	19.9	1102	63.2	0.94	0.81–1.10	0.93	0.80–1.09
4	1932	22.0	1213	62.8	0.93	0.80–1.08	0.90	0.77–1.05
5 (Most deprived)	2152	24.5	1348	62.6	0.92	0.80–1.07	0.89	0.76–1.04
Missing	110	1.3	44	40.0	0.37	0.25–0.55	0.37	0.25–0.56
Performance status
0	1626	18.5	1243	76.4	1.00		1.00
1	3208	36.6	2168	67.6	0.64	0.56–0.74	0.71	0.62–0.82
2	1664	19.0	903	54.3	0.37	0.31–0.42	0.45	0.38–0.52
3	683	7.8	279	40.8	0.21	0.18–0.26	0.27	0.22–0.33
4	53	0.6	20	37.7	0.19	0.11–0.33	0.23	0.13–0.41
Missing	1534	17.5	927	60.4	0.47	0.40–0.55	0.56	0.48–0.66
Charlson co-morbidity index
0	3318	37.8	2298	69.3	1.00		1.00
1	1641	18.7	1076	65.6	0.85	0.75–0.96	0.93	0.81–1.05
2-3	1092	12.5	669	61.3	0.70	0.61–0.81	0.81	0.70–0.94
>3	2717	31.0	1497	55.1	0.54	0.49–0.61	0.69	0.62–0.77
Stage
Extensive	4550	51.9	2712	59.6	1.00		1.00
Limited	2646	30.2	1889	71.4	1.69	1.53–1.87	1.44	1.29–1.61
Missing	1572	17.9	939	59.7	1.01	0.89–1.13	0.95	0.84–1.08
Time to treatment
<18 days	4305	49.1	2773	64.4	1.00		1.00
⩾18 days	4463	50.9	2767	62.0	0.90	0.83–0.98	0.81	0.74–0.89
Route of referral
Emergency admission	1157	13.2	626	54.1	0.56	0.49–0.64	0.68	0.59–0.78
General Practitioner	4666	53.2	3166	67.9	1.00		1.00
Consultant referral	1556	17.7	950	61.1	0.74	0.66–0.84	0.85	0.75–0.97
Other (inc private)	464	5.3	282	60.8	0.73	0.60–0.89	0.80	0.66–0.98
Emergency Department	514	5.9	269	52.3	0.52	0.43–0.63	0.63	0.52–0.77
Missing	411	4.7	247	60.1	0.71	0.58–0.88	0.82	0.66–1.01
Trust first seen
Non-chemotherapy trust	2064	23.5	1260	61.0	1.00		1.00
Chemotherapy trust	6688	76.3	4271	63.9	1.13	1.02–1.25	1.14	1.03–1.27
Missing/trust which saw <20 cases	16	0.2	9	56.3	0.82	0.30–2.21	0.63	0.23–1.72
Radiotherapy
No chemo-radiotherapy	7978	91.0	4919	61.7	1.00		1.00
Chemo-radiotherapy	790	9.0	621	78.6	2.29	1.92–2.72	1.74	1.44–2.09

Abbreviations: CI=confidence interval; OR=odds ratio

^aAnalysis restricted to people with SCLC who had record of chemotherapy in the Hospital Episodes Statistics databasel.

^bAdjusted for age, sex, socio-economic status, co-morbidity index, performance status and stage.